Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1058471

CCN(CC)CCN(C)C(=O)c1sc2c(c1OCC1CCCO1)c(=O)n(C)c1ccccc21.O=C(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.38
KMT2A Q03164 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 4/20 0.37
HPGD P15428 3/20 0.37
HSD17B10 Q99714 3/20 0.37
HTT P42858 1/20 0.37
ATM Q13315 1/20 0.35
SGMS1 Q86VZ5 1/20 0.35
SGMS2 Q8NHU3 1/20 0.35
TP53 P04637 2/20 0.35
HTR2A P28223 10/20 0.35
CYP3A4 P08684 3/20 0.35
MEN1 O00255 3/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SCD O00767 1/20 0.35
MAPT P10636 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10314421 0.96 KDM4E (0.41) KDM4EKMT2ASMN1; SMN2RAB9AALDH1A1
Trifluoroacetic Acid SCHEMBL1063970 0.88 KMT2A (0.48) KDM4EKMT2ASMN1; SMN2RAB9AALDH1A1
SCHEMBL1056680 0.86 KDM4E (0.44) KDM4EKMT2ASMN1; SMN2RAB9AALDH1A1
Trifluoroacetic Acid SCHEMBL1063419 0.85 TP53 (0.43) KDM4EKMT2AALDH1A1HSD17B10SGMS1
SCHEMBL1062554 0.85 TP53 (0.51) KDM4EKMT2ASMN1; SMN2RAB9AALDH1A1
Trifluoroacetic Acid SCHEMBL1062587 0.85 SGMS2 (0.42) KDM4EKMT2ASMN1; SMN2ALDH1A1HPGD
Trifluoroacetic Acid SCHEMBL1063966 0.85 KMT2A (0.43) KDM4EKMT2AALDH1A1HPGDHSD17B10
SCHEMBL1062598 0.85 KDM4E (0.45) KDM4EKMT2ASMN1; SMN2RAB9AALDH1A1
Trifluoroacetic Acid SCHEMBL1063002 0.84 KDM4E (0.37) KDM4EKMT2ASMN1; SMN2ALDH1A1HPGD
Trifluoroacetic Acid SCHEMBL1062740 0.84 KDM4E (0.38) KDM4EKMT2ASMN1; SMN2RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2247588-B1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-04-13 EP disclosed
US-8399449-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-03-19 US disclosed
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 KDM4E 528/4885KMT2A 453/4885SMN1; SMN2 3564/4885
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 KDM4E 464/4885KMT2A 386/4885SMN1; SMN2 3559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.